Default company panoramic image

Abionic SA

Based on an innovative nanotechnology approach, Abionic has developed a medical diagnostic device providing fast and low-cost allergy tests.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Chemin du Croset, Ecublens, VD, Switzerland
  • Currency CHF
  • Founded October 2010
  • Employees 8
  • Website

Company Summary

Abionic will change the game in allergy diagnosis by delivering with its first product, a novel, versatile in-vitro solution to provide instant quantitative diagnosis for allergies. Abionic is ISO 13485 certified. The company employs 8 highly qualified employees, has a strong board of directors and advisory board, and completed a Series A of EUR 1.6m with institutional investors. Abionic has received 14 awards from prestigious organisations.


  • Default avatar
    Nicolas Durand

    Dr. Nicolas Durand, founder and CEO – at EPFL Nicolas’ PhD thesis on Nanotechnologies applied to Life Sciences built Abionic's core technology. He was involved in the development of resonating biosensors at Carnegie Mellon University (USA), and was the winner of the 2006 Omega Award as well as the 2010 Young Entrepreneur Award. Nicolas was elected co-Captain of the Swiss Venture Leaders in 2010.

  • Default avatar
    Iwan Märki

    Dr. Iwan Märki, co-founder and CTO – Iwan is an expert in optical technologies. For over three years, he directed research into single molecule spectroscopy and imaging at the Laboratory of Biomedical Optics, EPFL. With a Master’s degree in microengineering (EPFL) and a PhD in nano-optical devices (IMT, Neuchâtel), he has the key competences to combine Abionic’s technologies into innovative products.